Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · bladder-landscape@3

DRR168609

—

ef5cafcc-a68b-5cf6-977c-382d698ff472

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—
sex
Male

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.710
  • ANGIOGENESIS+0.660
  • TGF_BETA_SIGNALING+0.480
  • UV_RESPONSE_DN+0.440
  • HEDGEHOG_SIGNALING+0.420
  • APICAL_JUNCTION+0.390
  • COAGULATION+0.390
  • KRAS_SIGNALING_UP+0.380
  • E2F_TARGETS+0.360
  • TNFA_SIGNALING_VIA_NFKB+0.330

Top 10 suppressed

  • MYC_TARGETS_V2-0.500
  • INTERFERON_ALPHA_RESPONSE-0.490
  • OXIDATIVE_PHOSPHORYLATION-0.390
  • PEROXISOME-0.300
  • FATTY_ACID_METABOLISM-0.260
  • REACTIVE_OXYGEN_SPECIES_PATHWAY-0.240
  • INTERFERON_GAMMA_RESPONSE-0.230
  • KRAS_SIGNALING_DN-0.220
  • ADIPOGENESIS-0.210
  • DNA_REPAIR-0.190

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1TCGA-HD-7753-01A-11R-2081-07
head-neck@1
——0.887
2SAMN03290934
melanoma-umap@29
——0.884
3TCGA-55-7726-01A-11R-2170-07
lung-landscapes@6
—cohortSQ10.874
4TCGA-BH-A0AV-01A-31R-A115-07
breast-umap@18
—E0.873
5SRR8943032
bladder-landscape@3
——0.855
6TCGA-D8-A142-01A-11R-A115-07
breast-umap@18
—E0.845
7TCGA-85-A50M-01A-21R-A262-07
lung-landscapes@6
—cohortSQ10.843
8TCGA-60-2704-01A-11R-2045-07
lung-landscapes@6
—cohortSQ10.837
9TCGA-A8-A07E-01A-11R-A034-07
breast-umap@18
—A0.835
10TCGA-44-8119-01A-11R-2241-07
lung-landscapes@6
—cohortA30.833

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 32 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
EPITHELIAL_MESENCHYMAL_TRANSITION0.710Inavolisib— uncovered
ANGIOGENESIS0.660Remibrutinib— uncovered
TGF_BETA_SIGNALING0.480Inavolisib— uncovered
UV_RESPONSE_DN0.440Inavolisib— uncovered
HEDGEHOG_SIGNALING0.420Inavolisib— uncovered
APICAL_JUNCTION0.390Inavolisib— uncovered
COAGULATION0.390Binimetinib— uncovered
KRAS_SIGNALING_UP0.380Inavolisib— uncovered
E2F_TARGETS0.360Inavolisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.330Inavolisib— uncovered
G2M_CHECKPOINT0.320Inavolisib— uncovered
MITOTIC_SPINDLE0.300Inavolisib— uncovered
INFLAMMATORY_RESPONSE0.270Idelalisib— uncovered
HYPOXIA0.260Idelalisib— uncovered
IL6_JAK_STAT3_SIGNALING0.260Inavolisib— uncovered
MYOGENESIS0.260Inavolisib— uncovered
NOTCH_SIGNALING0.220Inavolisib— uncovered
ANDROGEN_RESPONSE0.210Inavolisib— uncovered
PROTEIN_SECRETION0.210Remibrutinib— uncovered
IL2_STAT5_SIGNALING0.200Idelalisib— uncovered